Nurix Therapeutics, Inc.
NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for thā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$18.63
Price+0.76%
$0.14
1Y
Price
Market Cap
$1.432b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1031.4%
EBITDA Margin-1094.8%
Net Profit Margin-761.3%
Free Cash Flow Margin-1031.4%
EBITDA Margin-1094.8%
Net Profit Margin-761.3%
Free Cash Flow MarginRevenue
$83.687m
+53.4%
1y CAGR+41.2%
3y CAGR+38.4%
5y CAGREarnings
-$244.785m
-26.5%
1y CAGR-13.6%
3y CAGR-23.7%
5y CAGREPS
-$2.97
-3.1%
1y CAGR+5.6%
3y CAGR-4.8%
5y CAGRBook Value
$372.252m
$522.472m
Assets$150.220m
Liabilities$56.486m
DebtDebt to Assets
10.8%
-0.2x
Debt to EBITDAFree Cash Flow
-$241.360m
-32.7%
1y CAGR-29.2%
3y CAGR-44.6%
5y CAGRNo items found.
Press Releases
Statements and updates from the company